Spruce Biosciences reports Q3 2026 results, plans BLA submission for TA-ERT in December

Spruce Biosciences reported its third quarter 2026 financial results and provided corporate updates on its clinical pipeline. Management said it is completing final steps toward a planned BLA submission for TA-ERT, anticipated in December.

Detected & updated continuously · Source: Nebula